NLRP3 and COVID-19: In addition to other anti-inflammatory effects, colchicine has been shown to inhibit microtubule-driven spatial arrangement of mitochondria, thus preventing full NLRP3 inflammasome activation (65) and its use has been also reported to have beneficial effects in outpatients but not in hospitalized COVID-19 patients in recent clinical trials (66–68).